Seizures associated with memantine use

American Journal of Health-System Pharmacy

Volumn 62, Issue 4, 2005, Pages 420-421

  Peltz, Gayle ^a   Pacific, Domenica M ^b   Noviasky, John A ^c,e   Shatla, Ahmed ^d   Mehalic, Theodore ^c  

^a Department of Obstetrics and Gynecology   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c SEMC   (United States)

^d Shatla Neurology   (United States)

^e St Elizabeth Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE BESYLATE; DONEPEZIL; LATANOPROST; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; RIVASTIGMINE; SERTRALINE; VITAMIN B GROUP;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DISEASE PREDISPOSITION; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERIATRIC PATIENT; GLAUCOMA; HUMAN; HYPERTENSION; NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SEIZURE; TREATMENT OUTCOME;

EID: 15444369432     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.4.420     Document Type: Article

References (8)

1. Namenda (memantine hydrochloride) package insert. St. Louis, MO: Forest Pharmaceuticals; 2003 Oct.
2. Hutchinson TA, Shahan DR, eds. DRUG-DEX system. Greenwood Village, CO: Micromedex. Edition expires 2004 Mar.
3. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291:317-24.
4. Reisberg B, Doody R, Stöffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348:1333-41.
5. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
6. Boehm G. NDA safety review of memantine. www.fda.gov/ohrms/dockets/ac/03/ briefing/3979B1_04_FDA-Safety%20Review.pdf (accessed 2004 May 11).
7. Hassenbusch SJ, Satterfield WC, Gradert TL et al. Preclinical toxicity study of intrathecal administration of the pain relievers dextrorphan, dextromethorphan, and memantine in the sheep model. Neuromodulation. 1999; 2:230-40.
8. Pisani F, Oteri G, Costa C et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002; 25:91-110.